Business Wire

HSBC Continental Europe: Interim Results 2024

31.7.2024 12:00:00 EEST | Business Wire | Press release

Share

Regulatory News:

On 30 July 2024, HSBC Continental Europe’s Board of Directors approved the consolidated financial statements for the first half of 2024.

Andrew Wild, CEO of HSBC Continental Europe, said:

“We delivered a strong performance during the first half of 2024 which demonstrates the effectiveness of our strategy, leveraging on our global franchise and our international connectivity. Our ambition is to be the leading international wholesale bank in Europe servicing corporates and financial institutions, complemented by a targeted wealth and private banking offering.”

Profit before tax1 was €502m for the first half of 2024, driven by wholesale banking revenues, coupled with low credit losses and continued cost discipline.

Net operating income before change in expected credit losses and other credit impairment charges1 was €1,672m, down from €1,885m in the first half of 2023, due to lower net interest income following the sale of retail banking operations in France. Wholesale revenues in Commercial Banking and Global Banking remained strong, with growth in Global Payment Solutions and Investment Banking, partly offset by lower lending volumes. Revenues in Markets and Securities Services were down compared to the first half of 2023, with lower client activity in Global Debt Markets in the context of a challenging market environment, partly offset by higher revenues in Equities and Securities Financing.

Change in expected credit losses and other credit impairment charges1 wasa charge of €18m, compared with a charge of €16m in the first half of 2023. The cost of risk2, at 7bps, remained low but was driven by provision releases that are not expected to re-occur in the second half of 2024.

Operating expenses1were€1,152m, compared to €1,126m in the first half of 2023. Higher infrastructure and technology costs and the acquisition of HSBC Private Bank (Luxembourg) S.A. were partly offset by lower contributions to the Single Resolution Fund.

Profit after tax for the period was €370m, down from €1,944m in the first half of 2023 which included the reversal of the impairment previously recognised in relation to the sale of retail banking operations in France of €1.9bn pre-tax3.

The consolidated balance sheet of HSBC Continental Europe showed total assets of €280bn at 30 June 2024, compared to €283bn at 31 December 2023.

At 30 June 2024, HSBC Continental Europe reported an average liquidity coverage ratio (LCR)4 of 156% and a net stable funding ratio (NSFR)5 of 136%. The bank’s fully loaded common equity tier 1 (CET1) ratio was 15.1% and the fully loaded total capital ratio was 19.8%. The fully loaded leverage ratio was 4.3%. The solvency ratio of the Insurance subsidiary was 287%6.

Appendix

Interim accounts were subject to a limited review by the statutory auditors.

Summary consolidated income statement

€m

Half year to 30 June 2024

Half year to 30 June 2023

Continuing operations

Net interest income

941

1,173

Net fee income

594

585

Net income from financial instruments held for trading or managed on a fair value basis

114

61

Other operating income/(expense)

23

66

Net operating income before change in expected credit losses and other credit impairment charges

1,672

1,885

Change in expected credit losses and other credit impairment charges

(18)

(16)

Total operating expenses

(1,152)

(1,126)

Profit/(loss) before tax

502

743

Tax expense

(132)

(187)

Profit/(loss) after tax in respect of continuing operations

370

556

Profit/(loss) after tax in respect of discontinued operations

—

1,388

Profit/(loss) after tax for the period

370

1,944

Profit/(loss) attributable to shareholders of the parent company

350

1,933

Profit/(loss) attributable to non-controlling interests

20

11

Profit/(loss) for the period by global business

Continuing Operations

Wealth and Personal Banking

Commercial Banking

Markets and Securities Services

Global Banking

Global Banking and Markets Other

Corporate Centre

Total

€m

Half year to 30 June 2024

Net operating income before change in expected credit losses and other credit impairment charges

290

693

400

392

7

(110)

1,672

o/w net interest income/(expense)

202

494

113

203

13

(84)

941

Change in expected credit losses and other credit impairment charges

5

(30)

—

10

1

(4)

(18)

Total operating expenses

(204)

(319)

(361)

(214)

(11)

(43)

(1,152)

Profit/(loss) before tax

91

344

39

188

(3)

(157)

502

Half year to 30 June 2023

Net operating income before change in expected credit losses and other credit impairment charges

313

712

433

369

8

50

1,885

o/w net interest income/(expense)

280

530

105

211

6

41

1,173

Change in expected credit losses and other credit impairment charges

8

22

1

(48)

1

—

(16)

Total operating expenses

(185)

(290)

(394)

(189)

(17)

(51)

(1,126)

Profit/(loss) before tax

136

444

40

132

(8)

(1)

743

Business disposal – Retail banking operations in France

On 1 January 2024, HSBC Continental Europe completed the sale of its retail banking operations in France to CCF, a subsidiary of Promontoria MMB SAS (‘My Money Group’). The sale also included HSBC Continental Europe’s 100% ownership interest in HSBC SFH (France) and its 3% ownership interest in Crédit Logement.

Upon being classified as held for sale in 2023, retail banking operations in France met the criteria of discontinued operations classification and presentation under IFRS 5. Accordingly, the profit/(loss) of the discontinued operations as of June 2023 amounting to €1.4bn has been reported separately in the income statement, including the reversal of pre-tax IFRS 5 loss of €1.9bn.

HSBC Continental Europe

Headquartered in Paris, HSBC Continental Europe is an indirectly held subsidiary of HSBC Holdings plc. HSBC Continental Europe principally comprises, in addition to its banking, insurance and asset management activities based in France, the business activities of 10 European branches (in Belgium, Czech Republic, Germany, Ireland, Italy, Luxembourg, Netherlands, Poland, Spain and Sweden) and two bank subsidiaries in Continental Europe (in Luxembourg and Malta). HSBC Continental Europe’s mission is to serve both customers in Continental Europe for their needs worldwide and customers in other Group countries for their needs in Continental Europe.

HSBC Holdings plc

HSBC Holdings plc, the parent company of the HSBC Group, is headquartered in London. HSBC serves customers worldwide from offices in 60 countries and territories. With assets of US$2,975bn at 30 June 2024, HSBC is one of the world’s largest banking and financial services organisations.

Disclaimer

This press release contains certain forward-looking statements with respect to the financial condition, results of operations and business of the entity. Statements that are not historical facts, including statements about the entity’s beliefs and expectations, are forward-looking statements. Words such as ‘expects’, ‘anticipates’, ‘intends’, ‘plans’, ‘believes’, ‘seeks’, ‘estimates’, ‘potential’ and ‘reasonably possible’, variations of these words and similar expressions are intended to identify forward-looking statements. These statements are based on current plans, estimates and projections, and therefore undue reliance should not be placed on them. Forward-looking statements speak only as of the date they are made. HSBC Continental Europe makes no commitment to revise or update any forward-looking statements to reflect events or circumstances occurring or existing after the date of any forward-looking statement. Forward-looking statements involve inherent risks and uncertainties. Readers are cautioned that a number of factors could cause actual results to differ, in some instances materially, from those anticipated or implied in any forward-looking statements.

__________________________________
1 In respect of continuing operations. Retail banking operations in France met the criteria of discontinued operations classification under IFRS 5 in 2023. Accordingly, the profit/(loss) of the discontinued operations as of June 2023 has been reported separately.
2 Annualised cost of risk divided by customer loans outstanding at the end of the period.
3 As the sale no longer met the criteria for the operations to be classified as held for sale in the first half of 2023. The impairment was recognised again in the second half of 2023 ahead of the completion of the sale on 1 January 2024.
4 Computed in respect of the EU Delegated act.
5 Computed in respect of CRR II (Regulation EU 2019/876).
6 LCR, NSFR and the solvency ratio of the Insurance subsidiary are unaudited.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240731545246/en/

Contacts

Raphaële-Marie Hirsch
raphaele.marie.hirsch@hsbc.fr
+33 (0) 7 64 57 35 55

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Angel Aligner Unveils Six Innovations for 202711.11.2026 18:23:00 EET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel”), a global clear aligner leader, has unveiled six new clinical innovations, including SuperElastic (MC-SE)* aligner material, a Deepbite Solution for significantly expanded indications, and the Adapt-MATMsystem for next generation growth guidance for young patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261110338654/en/ Unveiling Angel's 2027 Innovations. Orthodontists and opinion leaders have long remarked about Angel’s clinical excellence. Orthodontics educator and thought leader Dr. David Sarver said: “In over 4 decades, I’ve never had a parent say I’d be happy if you ensure that my child’s treatment results are average.” Angel is committed to elevating the orthodontic specialty well above the average, especially as more competition and harder referral cases demand outstanding results. Bindu Saran, VP of Product Strategy, added: “Angel was founded by orthodontic profe

Abu Dhabi Future Health Summit Concludes with Research Partnerships and New Programmes to Advance Prevention and Health Innovation11.11.2026 16:58:00 EET | Press release

Held under the patronage of His Highness Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Chairman of the Abu Dhabi Executive Council, Abu Dhabi Future Health Summit 2026 concluded with agreements and initiatives spanning drug discovery, clinical research, preventive and reproductive health, alongside research and entrepreneurship programmes that will sustain collaboration beyond the Summit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111545964/en/ The Summit is the annual flagship gathering of Future Health – A Global Initiative by Abu Dhabi, curated and convened by the Department of Health – Abu Dhabi (DoH) together with Founding Partners PureHealth, M42, Institute for Healthier Living Abu Dhabi (IHLAD) and Mubadala Bio. Held from 20–22 October, the Summit attracted more than 17,300 visitors from 85 countries. It brought together health leaders, researchers, policymakers, investors and inn

De' Longhi Group: Record Results for the Quarter, With Revenue Growing by 7.7% and Net Profit Pertaining to the Group Progressing Significantly by 19%11.11.2026 16:58:00 EET | Press release

The Board of Directors of De' Longhi S.p.A. approved the consolidated results1 for the nine months of 2026. In the nine months the Group achieved: revenues for € 2,621.3 million, up by 6.5% with respect to 2025 (+7.7% at constant currency); an adjusted2 Ebitda of € 455.2 million, equal to 17.4% on revenues (vs. 15.8% with respect to last year); a net income pertaining to the Group equal to € 225.8 million (+20.4% with respect to last year); a positive net financial position equal to € 606.0 million. CEO Fabio de' Longhi commented: “The Group delivered its thirteenth consecutive quarter of organic revenue growth, underscoring our proven ability to capitalize on industry opportunities and respond promptly to market evolution, while ensuring consistent performance across both divisions. The professional business recorded a strong acceleration, spanning all geographies and brands, with revenues growth exceeding 35% for both the quarter and the nine-month period, this against an already par

Starr Chile Assigned A Rating from AM Best11.11.2026 15:30:00 EET | Press release

Starr, a global insurance and investment organization, today announced that the global credit rating agency AM Best has assigned Starr International Seguros Generales S.A. (Starr Chile) a Financial Strength Rating of A (Excellent) and a Long-Term Issuer Credit Rating of a+ (Excellent). The outlook for both credit ratings is positive. The rating reflects Starr’s strong balance sheet and Starr Chile’s successful implementation of Starr’s business model. AM Best also cited Starr’s operating performance, a favorable business profile and enterprise risk management as key factors supporting the positive rating. “This strong rating is another important endorsement of Starr’s business model as we continue to build our presence in Latin America,” said Jeff Greenberg, chairman and co-CEO of Starr. “It reflects the financial strength, underwriting discipline and experienced teams that underpin our business around the world, reinforcing the confidence brokers and clients can place in Starr.” Starr

Epinal, Inc. Emerges from Stealth with First-of-Its-Kind Breakthrough Semiconductor Electrochemical Biosensor (SEB) for Detection of Narcotics and Disease Biomarkers in Human Breath in Minutes11.11.2026 15:22:00 EET | Press release

Epinal, Inc., after over six years of under-the-radar development, has officially emerged from stealth mode, introducing a breakthrough Semiconductor Electrochemical Biosensor (SEB) designed to detect narcotics and disease biomarkers directly from human breath in minutes. By combining advanced semiconductors, electrochemical sensing, tailored protein engineering, and artificial intelligence, Epinal has addressed the historical sensitivity, selectivity, scaling, stability, and signal-to-noise limitations that have long bottlenecked biosensors. Epinal’s Semiconductor Electrochemical Biosensor (SEB) will be integrated into the next generation of low cost, disposable, single-use breathalyzer cartridges where the integrity of test results is of utmost importance. In the case of narcotic detection, a rapid, non-invasive, and objective result changes an outcome. End customers for Epinal’s SEB include breathalyzer manufacturers, healthcare, mobile computers & clinical smartphones, handheld bio

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye